- Home
- TOMZ vs CMMB Comparison
TOMZ vs CMMB Comparison
Compare TOMZ & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOMZ
- CMMB
- Stock Information
- Founded
- TOMZ 1979
- CMMB 2004
- Country
- TOMZ United States
- CMMB Israel
- Employees
- TOMZ N/A
- CMMB N/A
- Industry
- TOMZ Diversified Commercial Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- TOMZ Finance
- CMMB Health Care
- Exchange
- TOMZ Nasdaq
- CMMB Nasdaq
- Market Cap
- TOMZ 22.6M
- CMMB 23.0M
- IPO Year
- TOMZ N/A
- CMMB N/A
- Fundamental
- Price
- TOMZ $1.04
- CMMB $1.17
- Analyst Decision
- TOMZ Strong Buy
- CMMB Strong Buy
- Analyst Count
- TOMZ 1
- CMMB 2
- Target Price
- TOMZ $3.50
- CMMB $8.50
- AVG Volume (30 Days)
- TOMZ 35.3K
- CMMB 211.9K
- Earning Date
- TOMZ 07-31-2025
- CMMB 08-20-2025
- Dividend Yield
- TOMZ N/A
- CMMB N/A
- EPS Growth
- TOMZ N/A
- CMMB N/A
- EPS
- TOMZ N/A
- CMMB N/A
- Revenue
- TOMZ $8,201,313.00
- CMMB N/A
- Revenue This Year
- TOMZ $3.66
- CMMB N/A
- Revenue Next Year
- TOMZ $139.63
- CMMB N/A
- P/E Ratio
- TOMZ N/A
- CMMB N/A
- Revenue Growth
- TOMZ 19.09
- CMMB N/A
- 52 Week Low
- TOMZ $0.60
- CMMB $0.87
- 52 Week High
- TOMZ $1.50
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- TOMZ 54.54
- CMMB 40.31
- Support Level
- TOMZ $1.00
- CMMB $1.17
- Resistance Level
- TOMZ $1.12
- CMMB $1.24
- Average True Range (ATR)
- TOMZ 0.06
- CMMB 0.07
- MACD
- TOMZ -0.01
- CMMB -0.01
- Stochastic Oscillator
- TOMZ 21.05
- CMMB 34.67
About TOMZ TOMI Environmental Solutions Inc.
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. Its product portfolio includes The SteraPak, The Surface Unit, The Transport, The NV+, The Environment System, SteraMist Integrated System, BIT Solution, and Custom Engineered System.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.